Position in GSK
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$322,068
-$46,214 QoQ
Shares Held
6,144
-7.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#579
of 1,032 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in GSK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026ATALANTA SOSNOFF CAPITAL, LLC holds $180,479,355 across 9 Drug Manufacturers - General names. GSK ranks #7 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
77,995 | $93,549,550 | |
| 2 | MRK |
Merck & Co., Inc.
|
642,053 | $82,503,810 | |
| 3 | ABBV |
AbbVie Inc.
|
7,988 | $2,010,099 | |
| 4 | PFE |
Pfizer Inc
|
23,858 | $574,500 | |
| 5 | JNJ |
Johnson & Johnson
|
2,192 | $556,702 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
5,696 | $328,203 | |
| 7 | GSK |
GSK plc
This page
|
6,144 | $322,068 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
2,548 | $321,914 |
All Filings in GSK
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $322,068 | 6,144 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $368,282 | 6,673 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $329,744 | 6,724 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $300,134 | 6,954 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $273,600 | 7,125 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $267,887 | 6,915 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $207,113 | 6,124 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $232,157 | 5,679 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $218,641 | 5,679 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $252,804 | 5,897 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||